Retrospective analyses versus RCTs: comparing like with like?

Click to increase image sizeClick to decrease image size

Disclosure

Ralf Baron was the principal investigator of the study used for comparison. He received grants/research supports from Pfizer, Genzyme, Grünenthal, and Mundipharma. He is a member of EU Project No 633491 DOLORisk, German Federal Ministry of Education and Research (BMBF): ERA-NET NEURON, IM-PAIN Project, German Research Network on Neuropathic Pain, NoPain system biology, German Research Foundation (DFG). He received speaking fees from Pfizer, Genzyme, Grünenthal, Mundipharma, Sanofi Pasteur, Medtronic, Eisai, Lilly, Boehringer Ingelheim, Astellas, Desitin, Teva Pharma, Bayer-Schering, MSD, and Seqirus. He was also a consultant for Pfizer, Genzyme, Grünenthal, Mundipharma, Allergan, Sanofi Pasteur, Medtronic, Eisai, Lilly, Boehringer Ingelheim, Astellas, Novartis, Bristol-Myers-Squibb, Biogenidec, AstraZeneca, Merck, AbbVie, Daiichi Sankyo, Glenmark Pharmaceuticals, Seqirus, Teva Pharma, Genentech, and Galapagos. Lieven Nils Kennes was the statistician of the study used for comparison. Christian Elling is an employee of the study sponsor, Grünenthal GmbH. The authors report no other conflicts of interest in this communication.

Disclosure

MAU and GHHMS are physicians and independent of any significant/relevant financial or other relationship to the sponsor, except for minor reimbursements for occasional lecture or consulting fees. Both are honorary members of the management boards of the German Pain Association and the German Pain League. The German Pain Registry is hosted by an independent contract research organization by order of the German Pain Association and under control of the Institute of Neurological Sciences and collects standardized data from daily routine medical care since January 2000. During the last 2 years, MAU received financial support and/or expenses in the form of research money, consultancy fees, and/or remunerations for lecture activities from Almirall, Archimedes, Grünenthal, Kyowa Kirin, Menarini, MSD, Mucos, Mundipharma, Pfizer, PharmAllergan, Shionoghi, and TEVA. During the last 2 years, GHHMS received financial support and/or expenses in the form of research money, consultancy fees, and/or remunerations for lecture activities from Allergan, Almirall, Grünenthal, Kyowa Kirin, Mundipharma, Pfizer, PharmAllergan, Shionoghi, and TEVA. The authors report no other conflicts of interest in this communication.